Articles tagged with Vaccine Development
Pneumococcal disease is a leading vaccine-preventable killer of children under age five, causing life-threatening infections. Dr. Thomas Cherian's work has helped advance medical science and inform policy to overcome obstacles in awareness, financing, and vaccine access.
Scientists have developed an experimental VLP vaccine that protects macaques and mice against chikungunya virus, a debilitating disease with no current treatment. The vaccine, using non-infectious virus-like particles, elicits immune responses and provides complete protection from infection.
The rotavirus vaccine has been shown to prevent severe diarrhoea in African children, with a 61.2% reduction in incidence. The vaccine's efficacy was lower in Malawi compared to South Africa, but it still demonstrated significant impact in reducing mortality rates.
Researchers at Uppsala University have identified a biodegradable substance with higher activity than existing adjuvants, paving the way for therapeutic vaccines to be used as cost-effective treatments for diseases like cancer and allergies.
The HPV-16/18 AS04-adjuvanted vaccine (Cervarix) induces a strong and sustained antibody response and has a favourable safety profile. Vaccine efficacy against incident infection with HPV-16/18 was 95% and against 12-month persistent infection was 100%.
The Elsevier journal Vaccine has released a supplement dedicated to vaccines for biodefense, showcasing significant advancements in vaccine development against diverse human and veterinary pathogens. The publication acknowledges the shift from traditional military focus to protecting both civilian and military populations.
The National Institute of Allergy and Infectious Diseases has awarded approximately $208 million to two programs that support research on the human immune response to emerging and re-emerging infectious diseases. This funding aims to identify new vaccines and drug targets, with a focus on developing prevention tools and therapeutics.
Researchers identified 78 homegrown health biotechnology companies producing innovative products for all neglected diseases, including the Big 3. A proposed 'Global Health Accellerator' service aims to connect these firms with expertise and funding to reach additional villages worldwide.
The Walter and Eliza Hall Institute has received a US$100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation to develop a genetically attenuated live malaria vaccine. The project aims to provide strong and lasting immunity against Plasmodium falciparum, the parasite that causes deadly human malaria.
A systematic review of six randomized trials found pneumococcal conjugate vaccines reduced vaccine-type IPD by 80%, all-serotype IPD by 58% and x-ray defined pneumonia by 27%. The vaccines also prevented 11% of child deaths.
The Government of Canada is supporting scientific research to deepen knowledge of the H1N1 flu virus. Five new projects, totaling $2.4 million over two years, will investigate how to manage health-care resources during a pandemic, impact on pregnant women, and development of new drug therapies.
A study published in Virology demonstrates that the ancient pathogen cowpox still has much to teach us about developing novel vaccines. Researchers identified 9 new protective components of the virus, which offered superior protection in a mouse model compared to existing vaccines.
A new method of delivering measles vaccines, using an inhalable powder, has shown promise in test animals. The powder is produced by mixing a weakened measles virus with high-pressure carbon dioxide and can remain stable for at least eight weeks at room temperature.
The MSD Wellcome Trust Hilleman Laboratories aims to develop new vaccines to prevent diseases affecting low-income countries. The not-for-profit joint venture will work on optimizing existing vaccines and developing new ones, with the goal of increasing vaccine impact in resource-limited settings.
Researchers at Oregon State University have developed a new vaccine adjuvant using lecithin nanoparticles, which showed improved immune response and reduced toxicity compared to existing alum-based adjuvants. The new adjuvant could potentially become a universal carrier for vaccines and help tackle various diseases more effectively.
The new initiative will characterize the human immune system under normal conditions and following infection or vaccination, using systems biology approaches. Researchers will analyze human samples from well-characterized cohorts to identify specific patterns of immune molecules that reflect immune system function.
A dry powder inhalable measles vaccine is being developed for clinical trials in India, which could save millions of lives annually. The vaccine uses a patented process called CAN-BD to create an inhalable powder that can be administered via a simple inhaler.
Researchers at Yerkes National Primate Research Center propose alternative approaches to developing an effective AIDS vaccine, including making infected individuals resistant to disease progression or reducing the number of cells the virus can infect. They draw inspiration from African nonhuman primates that adapt to HIV-like viruses i...
The University of Rhode Island has been awarded a $13 million grant from the National Institutes of Health to develop vaccines for emerging infectious diseases. The grant will fund research on immunome-derived vaccines, which have the potential to be safer and more effective than traditional vaccines.
A new study by IVI-NICED found that the Vi polysaccharide vaccine is highly effective in protecting young children against typhoid fever, with 80% protection rate in children under five years old. The vaccine also conferred substantial herd protection, reducing typhoid risk among unvaccinated neighbors by 44%.
Researchers have developed a malaria vaccine that effectively blocks the parasite's sexual development, critical for transmission. The vaccine induced a significant immune response in mice and non-human primates, with a 93% transmission-blocking rate after a single dose.
Nearly half of the world's population is at risk of malarial infection, causing over 250 million clinical episodes and one million deaths each year. Researchers identified key challenges in developing a protective malaria vaccine, including identifying which proteins provoke a strong immune response.
The Immune Epitope Database and Analysis Resource (IEDB) is the world's largest collection of scientific data on how the immune system responds to infectious diseases. With its 2.0 launch, researchers worldwide can now easily access and analyze over 95% of published information on immune epitope responses.
A MSU researcher has developed a working vaccine for Enterotoxigenic E. coli, responsible for 60% of all E. coli diarrheal disease. The vaccine could save untold lives and also provide relief from post-operative complications such as paralytic ileus and urinary retention.
A researcher at Northwestern University has developed a new oral vaccine using probiotics that induces a powerful immune response, protecting against diseases such as anthrax and breast cancer. The vaccine harnesses the body's primary immune force in the small intestine, bypassing traditional injection methods.
A study found that a tissue-cultured smallpox vaccine elicited high levels of seroconversion and an effective booster response in adults, with no severe adverse events reported. The vaccine's safety and immunogenicity were demonstrated in both previously vaccinated and unvaccinated individuals.
The Pneumonia Etiology Research for Child Health (PERCH) initiative aims to study the causes of pediatric pneumonia in five to ten countries, using modern diagnostics and methods to guide vaccine and treatment development. This effort could help prevent many pneumonia deaths and develop tools to tackle even more cases.
Researchers at UT Health Science Center are developing a vaccine targeting alpha-synuclein to prevent Parkinson's disease progression. The vaccine has the potential to slow symptom onset, a current challenge in treatment.
A five-year Canadian study led by Dr. Cécile Tremblay aims to develop new strategies to fight AIDS in individuals who naturally control their HIV infection progression. The study will analyze factors predicting favourable outcomes and identify drivers of HIV diversity.
A multidisciplinary approach predicts the immunity of a vaccine based on gene expression patterns and T cell responses. The study successfully predicted immunity in up to 90% accuracy using the yellow fever vaccine as a model.
A study led by Beth Israel Deaconess Medical Center demonstrates a T-cell-based HIV-1 vaccine strategy may be effective in fighting AIDS. The vaccine regimen induced potent immune responses, reducing viral replication and preventing AIDS development in monkeys.
The introduction of the pentavalent vaccine in Pakistan aims to protect its children against Haemophilus influenzae type b (Hib) and four other common childhood diseases. The vaccine is expected to save thousands of lives, particularly among the nation's poorest families.
A team of researchers has characterized a large number of parasite proteins that may prove useful in the development of a human malaria vaccine. These proteins are essential for sporozoite development, which can be genetically inactivated to stimulate an immune response.
A Phase III study found that the high-dose influenza vaccine increased immune responses to all three influenza strains compared to the standard vaccine in adults 65 years old and older. The new vaccine also showed increased immune response in those with no measurable protective antibodies before vaccination.
A new report highlights the urgent need to tackle pneumococcal disease, a leading cause of death among children under five. The UK All-Party Parliamentary Group recommends increasing vaccine availability and healthcare system strengthening in developing countries to reduce child mortality rates.
Researchers at Aberystwyth University have licensed a discovery of a protein that can 'wake up' dormant Mycobacterium tuberculosis bacteria, potentially leading to the development of a more effective vaccine. The Aeras Global TB Vaccine Foundation plans to take its recombinant BCG (AERAS-407) vaccine to clinical trial in 2009.
Researchers have identified a key role for cytokine interleukin 17 in immune system detection of pneumococcus. This discovery may help develop an effective and affordable vaccine for the disease, which affects young children and the elderly.
Researchers at Boston Children's Hospital have discovered a new mechanism of immunity that could lead to the development of a more effective pneumococcal vaccine. The study identified specific protective T-cells called TH17 cells, which release protein IL-17 to kill pneumococcus in the nose, significantly reducing the risk of infection.
Researchers will develop oral vaccines against tetanus and rotavirus, targeting vulnerable infants and young children. The goal is to create a vaccine that doesn't contain live bacteria and has fewer side effects.
Researchers at UTMB have tested a new universal vaccine effective against multiple influenza strains, with promising results in a Phase I clinical trial. The vaccine candidate, VaxInnate's M2e, could provide a safe and highly effective solution to prevent seasonal and pandemic influenza A.
A vaccine for tularemia, caused by Francisella tularensis, is being developed as the disease's potential as a bioterrorism agent has increased. Researchers have made progress in understanding the bacterium's pathogenesis and identifying potential targets for a vaccine.
A University of California, San Diego researcher has created a novel culture system that models HCV infection in human liver cells, providing a realistic environment to test new treatments. This breakthrough enables the screening of possible therapies for HCV, which affects approximately 170 million people worldwide.
A third of the world's population is infected with M. tuberculosis, and two million people die from tuberculosis every year. New, improved vaccines or vaccination strategies are urgently needed to reduce the immense burden of this disease.
Researchers at Thomas Jefferson University have developed a new type of colon cancer vaccine that reduces the spread of disease in mice. The vaccine targets mucosal cells and induces an immune response against cancer, leading to fewer metastases and prolonged survival.
A new mathematical model could lead to personalized vaccines for CML patients, strengthening the immune system during its weakest point. The study uses data from four years of imatinib therapy and recommends 'cancer vaccines' to combat drug resistance.
Scientists at La Jolla Institute for Immunology discovered a previously unknown mechanism in how the body responds to viruses, illuminating a new approach to developing vaccines. The finding reveals that B cells and CD4 T cells recognize the same piece of the virus, narrowing down the search for antigens.
Researchers at the University of Texas Medical Branch have created new vaccines for West Nile and Japanese encephalitis viruses, showing promise in providing immunity against these deadly diseases. The 'pseudoinfectious' vaccines use genetically modified viruses that can only infect a single cell, mimicking a viral infection without am...
A unique HIV vaccine formulation has been shown to induce strong and balanced immune responses in healthy human volunteers. The combination approach used in the study achieved high titer antibodies that recognized a diverse group of HIV envelope proteins, providing promising results for future efforts to optimize HIV vaccine formulations.
Advances in sequencing and surveillance have enabled researchers to identify circulating strains of HIV-1, with subtype B prevalent in the Americas and clades A, C, and D in Sub-Saharan Africa. The study highlights the importance of viral diversity on disease progression and transmission.
A new vaccine under development has shown promising results in mice, protecting against highly pathogenic bird flu and its variants for a year or longer. The vaccine uses an adenovirus vector technology, which can be produced quickly and stored for long periods, making it an attractive option for pandemic preparedness.
A new HIV/AIDS vaccine is being tested in a phase 1 clinical trial at Beth Israel Deaconess Medical Center in Boston. The vaccine uses a replication-incompetent adenovirus vector encoding an HIV-1 envelope gene, aiming to overcome the problem of preexisting immunity to common vaccine vectors.
The George Institute is tracking global funding for R&D of neglected diseases in developing countries through a 5-year survey. The study aims to provide donors with an updated overview of investment gaps and prevent duplication of efforts.
Scientists at the University of Adelaide are developing new vaccines and treatments to combat hepatitis C, a virus affecting over 170 million people worldwide. The five-year project aims to identify antiviral proteins and improve treatment options, offering hope for those suffering from the disease.
Researchers at the University of Pittsburgh's Center for Vaccine Research have developed a vaccine against the deadliest strain of avian flu, H5N1. The vaccine produced a strong immune response in mice and protected them from death following infection with the virus.
Researchers have developed new tools to understand HIV immune evasion. Vaccination timing significantly affects the rate of immune escape in macaques, suggesting ways to improve HIV vaccines.
Researchers at Queen's University have found a way to manipulate the immune system by introducing virus components that activate killer T cells. This discovery may lead to more effective vaccines against diseases like influenza or HIV, as well as enhanced immunology treatments.
Scientists have discovered a way to eliminate the negative effect of M2 protein on anti-flu vaccination, increasing efficacy while maintaining safety. This breakthrough could lead to more effective and strain-specific vaccines against seasonal flu.
Dengue fever, a mosquito-borne illness, is becoming increasingly prevalent along the U.S.-Mexico border and in Puerto Rico. The NIAID experts warn that widespread dengue cases in the continental US are a real possibility due to the lack of effective treatments or vaccines.
A new study suggests that a vaccine targeting Epstein-Barr virus may prevent infectious mononucleosis, commonly known as “mono” or “glandular fever.” The vaccine was found to reduce the proportion of symptomatic EBV infections from 10% in control groups to 2% in vaccinated individuals.
A recent study reveals that CMV retinitis is causing blindness in young people with HIV in the developing world, often leading to fatal outcomes. Successful management of the disease requires decentralizing diagnostic capacity and making valganciclovir medication affordable.